The effect of antitumor drugs on the course of tuberculosis in the experiment
- Authors: Kudriashov G.G.1, Vinogradova T.I.1, Zmitrichenko Y.G.2, Dogonadze M.Z.1, Zabolotnyh N.V.1, Dyakova M.E.1, Esmedlyaeva D.S.1, Gavrilov P.V.1, Azarov A.A.1, Tochilnikov G.V.2, Nefedov A.O.1, Krylova Y.S.1, Yablonskii P.K.1,3
-
Affiliations:
- Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
- N.N. Petrov National Medicine Research Center of oncology
- Federal State Budgetary Educational Institution of Higher Education «Saint-Petersburg State University»
- Issue: Vol 21, No 2 (2023)
- Pages: 25-32
- Section: Original research
- URL: https://journals.eco-vector.com/1728-2918/article/view/340848
- DOI: https://doi.org/10.29296/24999490-2023-02-04
- ID: 340848
Cite item
Open Access
Access granted
Abstract
Introduction. Lung cancer and tuberculosis, make a significant affect to the morbidity and mortality of the population in Russia and in the world. Strategy of medication therapy has not been developed for cases when these diseases are combined.
The aim of the study was to investigate the effect of antitumor therapy on the course of pulmonary tuberculosis in an experiment. The research was supported by a grant from the Russian Science Foundation No. 22-15-00470 (https://rscf.ru/project/22-15-00470/)
Material and methods. The study was performed on 109 mice of the C57BL/6 line at the age of two months. The animals were infected with the reference strain of Mycobacterium tuberculosis (MTB) H37Rv. Antitumor drugs (that used in the treatment regimens of non-small cell lung cancer) were injected intraperitoneally in monotherapy mode. 10 groups were formed: 1 – intact mice 9 (n=10); 2 – mice infected with MTB, without treatment (n=19); 3 – mice infected with MBT + cisplatin injection 10 mg/kg (n=10); 4 – mice infected with MBT + carboplatin injection 100 mg/kg (n=10); 5 – mice infected with MTB + gemcitabine injection 300 mg/kg (n=10); 6 – mice infected with MTB + pemetrexed injection 167 mg/kg (n=10); 7 – mice infected with MTB + etoposide injection 40 mg/kg (n=10); 8 – mice, infected with MTB + paclitaxel injection 30 mg /kg (n=10); 9 – mice infected with MTB + docetaxel injection 30 mg/kg (n=10); 10 – mice infected with MTB + vinorelbin injection 10 mg/kg (n=10). Comparison of clinical, radiological, and laboratory parameters was performed using nonparametric statistics methods. The survival rate was analyzed using the Kaplan-Meyer method.
Results. There was a decrease in body weight in all groups of mice infected with MTB compared to intact animals. The lowest body weight gain was observed in group 8, and the greatest increase in group 3. Infiltrative-focal changes in the lungs were detected during computed tomography less frequently in groups 3, 4, 9, 10 in comparison with the control (group 2). The lowest total lung lesion index was recorded in groups 10, 9 and 4 (less than in infection control group). In groups 3, 6, 7, 8 tuberculous lung lesions were more common than in group 2. The most common exudative changes were recorded in groups 3 and 7, and productive changes in groups 6 and 7. The highest level of mycobacterial load was recorded in the lungs of mice in group 7 after etoposide injection. Low survival was observed in groups 3, 5, 10. The highest survival rates were recorded in groups 4, 6, 8.
Conclusion. The results of the complex analysis allow us to consider carboplatin and docetaxel as the most promising drugs for the treatment of malignant lung tumors in patients with combined pathology.
Full Text
About the authors
Grigorii G. Kudriashov
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: dr.kudriashov.gg@yandex.com
ORCID iD: 0000-0002-2810-8852
Senior Research Associate, thoracic surgeon, MD, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Tatiana I. Vinogradova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: ti.vinogradova@spbniif.ru
ORCID iD: 0000-0002-5234-349X
Project Leader, MD, PhD, Dr. Sci. (Med.)
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Yuliya G. Zmitrichenko
N.N. Petrov National Medicine Research Center of oncology
Email: zmitrichenko@gmail.com
ORCID iD: 0000-0002-9137-9532
Junior Research Associate, Scientific Laboratory of Cancer Chemoprophylaxis and Oncopharmacology
Russian Federation, Leningradskaya str., 68, village Pesochny, St. Petersburg, 197758Marine Z. Dogonadze
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: marine-md@mail.ru
ORCID iD: 0000-0002-9161-466X
Senior Research Associate, MD, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Natalia V. Zabolotnyh
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: info@spbniif.ru
ORCID iD: 0000-0002-2946-2415
Leading Research Associate, MD, PhD, Dr. Sci. (Med.)
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Marina E. Dyakova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: marinadyakova@yandex.ru
ORCID iD: 0000-0002-7810-880X
Senior Research Associate, PhD, Dr. Sci.
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Dilyara S. Esmedlyaeva
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: diljara-e@yandex.ru
ORCID iD: 0000-0002-9841-0061
Senior Research Associate, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Pavel V. Gavrilov
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: spbniifrentgen@mail.ru
ORCID iD: 0000-0003-3251-4084
Leading Research Associate, MD, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Artem A. Azarov
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: azardoc0@gmail.com
ORCID iD: 0000-0002-4898-5991
Postgraduate Student
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Grigorii V. Tochilnikov
N.N. Petrov National Medicine Research Center of oncology
Email: gr75@mail.ru
ORCID iD: 0000-0003-4232-8170
Head of the Scientific Laboratory of Cancer Chemoprophylaxis and Oncopharmacology, MD, PhD
Russian Federation, Leningradskaya str., 68, village Pesochny, St. Petersburg, 197758Andrey O. Nefedov
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: herurg78@mail.ru
ORCID iD: 0000-0001-6228-182X
Senior Research Associate, Head of the Department of Thoracic Oncology, MD, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Yulia S. Krylova
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Email: emerald2008@mail.ru
ORCID iD: 0000-0002-8698-7904
Senior Research Associate, Center for Molecular Biomedicine, MD, PhD
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036Piotr K. Yablonskii
Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education «Saint-Petersburg State University»
Author for correspondence.
Email: glhirurgb2@mail.ru
ORCID iD: 0000-0003-4385-9643
Director, MD, PhD, Dr. Sci. (Med.), professor
Russian Federation, Ligovsky av., 2–4, St. Petersburg, 191036; Universitetskaya embankment, 7/9, Saint Petersburg, 199034References
- Zhou Y., Cui Z., Zhou X., Chen C., Jiang S., Hu Z., Jiang G. The presence of old pulmonary tuberculosis is an independent prognostic factor for squamous cell lung cancer survival. J. of Cardiothoracic surgery. 2013; 8: 1–5.
- Крылова Ю.С., Кудряшов Г.Г., Нефедов А.О., Дохов М.А., Захарченко А.О., Яблонский П.К. Сигнальные молекулы опухолевой трансформации при туберкулезе. Молекулярная медицина. 2022; 20 (6): 12–5. https://doi.org/10.29296/24999490-2022-06-02 [Krylova Yu.S., Kudriashov G.G., Nefedov A.O., Dokhov M.A., Zakharchenko A.O., Yablonskii P.K. Signaling molecules of tumor transformation in tuberculosis. Molekulyarnaya meditsina. 2022; 20 (6): 12–5. https://doi.org/10.29296/24999490-2022-06-02 (in Russian)].
- Новицкая Т.А., Ариэль Б.М., Двораковская И.В., Аветисян А.О., Яблонский П.К. Морфологические особенности сочетания туберкулеза и рака легких. Архив патологии. 2021; 83 (2): 19–24. DOI: 10.17116/ patol20218302119 [Novickaja T.A., Arijel’ B.M., Dvorakovskaja I.V., Avetisjan A.O., Jablonskij P.K. Morfologicheskie osobennosti sochetanija tuberkuleza i raka legkih. Arhiv patologii. 2021; 83 (2): 19–24 DOI: 10.17116/ patol20218302119 (in Russian)].
- Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Моисеенко Ф.В., Реутова Е.В., Тер-Ованесов М.Д. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2021; 11 (3S2-1): 36–54. doi: 10.18027/2224-5057-2021-11-3s2-02 [Laktionov K.K., Artamonova E.V., Breder V.V., Gorbunova V.A., Moiseenko F.V., Reutova E.V., Ter-Ovanesov M.D. Prakticheskie rekomendacii po lekarstvennomu lecheniju nemelkokletochnogo raka legkogo. Zlokachestvennye opuholi. 2021; 11 (3S2-1): 36–54. DOI: 10.18027 / 2224-5057-2021-11-3s2-02 (in Russian)].
- Александрова А.Е., Ариэль Б.М. Оценка тяжести туберкулезного процесса в легких мышей. Проблемы туберкулеза. 1993; 3: 52–3. [Aleksandrova A.E., Arijel’ B.M. Ocenka tjazhesti tuberkuleznogo processa v legkih myshej. Problemy tuberkuleza. 1993; 3: 52–3 (in Russian)].
- Биохимические методы исследования в клинике. Под ред. А.А. Покровского. М.: «Медицина», 1969. [Biohimicheskiemetodyissledovanijavklinike. Pod red. A.A. Pokrovskogo. Moskva: «Medicina», 1969 (in Russian)].
- Giusti G. Adenosine deaminase. Methods of enzymatic analysis. Ed.H. Bergmeyer. New York: Academic Press; 1974.
- Kaljas Y., Liu C., Skaldin M., Wu C., Zhou Q., Lu Y., Aksentijevich I., Zavialov A.V. Human adenosine deaminases ADA1 and ADA2 bind to dfferent subsets of immune cells. Cell. Mol. Life Sci. 2017; 74 (3): 555–70. doi: 10.1007/s00018-016-2357-0.
- Кудряшов Г.Г., Нефедов А.О., Точильников Г.В., Змитриченко Ю.Г., Крылова Ю.С., Догонадзе М.З., Заболотных Н.В., Дьякова М.Е., Эсмедляева Д.С., Витовская М.Л., Гаврилов П.В., Азаров А.А., Журавлев В.Ю., Виноградова Т.И., Яблонский П.К. Оригинальная экспериментальная модель туберкулеза и рака легкого. Педиатр. 2022: 13 (5): 33–42. DOI: https://doi.org/10.17816/PED13533-42 [Kudrjashov G.G., Nefedov A.O., Tochil’nikov G.V., Zmitrichenko Ju.G., Krylova Ju.S., Dogonadze M.Z., Zabolotnyh N.V., D’jakova M.E., Jesmedljaeva D.S., Vitovskaja M.L., Gavrilov P.V., Azarov A.A., Zhuravlev V.Ju., Vinogradova T.I., Jablonskij P.K. Original’naja jeksperimental’naja model’ tuberkuleza i raka legkogo. Pediatr. 2022: 13 (5): 33–42. DOI: https://doi.org/10.17816/PED13533-42 (in Russian)]
- Гаврилов П.В., Виноградова Т.И., Азаров А.А. Ленская К.В., Романовская-Романько Е.А., Стукова М.А., Васильев К.А. , Крылова Ю.С., Пичкур Л.К., Заболотных Н.В., Соколович Е.Г., Яблонский П.К. Применение компьютерной томографии для мониторирования изменений в легких при тяжелых формах гриппа в эксперименте. Медицинский альянс. 2020; 4: 65–72. doi: 10.36422/23076348-2020-8-4-65-72 [Gavrilov P.V., Vinogradova T.I., Azarov A.A. Lenskaja K.V., Romanovskaja-Roman’ko E.A., Stukova M.A., Vasil’ev K.A. , Krylova Ju.S., Pichkur L.K., Zabolotnyh N.V., Sokolovich E.G., Jablonskij P.K. Primenenie komp’juternoj tomografii dlja monitorirovanija izmenenij v legkih pri tjazhelyh formah grippa v jeksperimente. Medicinskij al’jans. 2020; 4: 65–72. doi: 10.36422/23076348-2020-8-4-65-72 (in Russian)].
Supplementary files
